

OncoTherapy Science, Inc.

October 3, 2014

Announcement of the first-patient enrollment in phase I clinical trial
of the out-licensed antibody from the Consolidated Subsidiary of OncoTherapy

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that KHK6640, an anti-amyloid beta (A β) peptide antibody which was out-licensed from Immunas Pharma, Inc. (President & CEO: Kazuo Yamamoto; hereinafter, “Immunas”; a consolidated subsidiary of OncoTherapy) to Kyowa Hakko Kirin, Ltd. (Head office: Chiyoda-ku, Tokyo, President and CEO: Nobuo Hanai, hereinafter “Kyowa Hakko Kirin”), was administered to the first patient in phase I clinical trial in Europe.

This Clinical Trial is conducted to confirm the safety and tolerability of this anti-A β peptide antibody in patients with prodromal/mild/moderate Alzheimer’s disease.

This antibody is a monoclonal antibody which selectively binds to pathological aggregates of A β peptide. A β aggregates are thought to be one of the major factors involved in Alzheimer’s disease, and this antibody is expected to inhibit the progression of the disease.